Diasin RXD
Natural health product licensed in Canada
- Licence holder
- STP Pharmaceutical Corp
- NPN or DIN-HM
- 80070440
- Status
- Active licence
- Licence date
- 20 June 2016
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Chrome Source : Picolinate de chrome (III) | 100 microgrammes | Not calculated |
| Curcuma longa Source : Rhizome | 25 milligramme | Not calculated |
| Cinnamomum aromaticum Source : Écorce (tige) | 250 milligramme | Not calculated |
| Trigonella foenum-graecum Source : Trigonella foenum-graecum - Graine | 125 milligramme | Not calculated |
| Momordica charantia Source : Fruit | 25 milligramme | Not calculated |
Non-medicinal ingredients
Eau, Cellulose microcristalline, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
A factor in the maintenance of good health. Provides support for healthy glucose metabolism. Helps the body to metabolize carbohydrates and fats.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Effets indésirables connus
Hypersensitivity/allergy may occur; in which case, discontinue use. If you experience symptoms of hypoglycaemia including feelings of anxiety, dizziness, tremor, sweating, nausea or headache, discontinue use and consult a health care practitioner.
- Contre-indications
Do not use if you are pregnant or breastfeeding.
- Précautions et mises en garde
Consult a health care practitioner prior to use if you have a kidney disorder and/or diabetes. Consult a health care practitioner prior to use if you have gallstones or a bile duct obstruction. Consult a health care practitioner prior to use if you have stomach ulcers or excess stomach acid. Consult a health care practitioner if symptoms persist or worsen.
Source
Official Health Canada record, licence 80070440
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.